Breast Implant Makers Can Use Registries To Fulfill Post-Market Surveillance Duties
This article was originally published in The Gray Sheet
Executive Summary
After years of struggling to track breast implant patients with post-market surveillance surveys, silicone gel breast implant makers will be allowed by FDA to substitute data from two new registries to fulfill their duties on post-approval studies and device tracking, an FDA epidemiologist said recently.
You may also be interested in...
FDA Disputes Study On Breast Implant Safety
US FDA has taken the rare step of publicly disputing a study that seemed to show elevated risks of long-term adverse events associated with silicone breast implants.
CDRH Launches ‘Health Of Women’ Program; Research Agenda To Focus On Ortho, Cardio Devices
The device center plans to develop a research roadmap to explore sex-based differences in outcomes to musculoskeletal and cardiovascular disease devices, as well as devices targeting diseases specific to women. CDRH launched the effort as part of its new “Health of Women” initiative at a workshop last week.
FDA Considers National Registry For Silicone Breast Implants
Due to lower-than-expected follow-up rates for Allergan and Johnson & Johnson/Mentor’s silicone-gel-filled breast implant post-approval studies, FDA advisory panel members last week called for a national registry to better document long-term outcomes and complications.